Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Taps Avant’s Phase II Brain Cancer Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Therapeutic vaccine is a “beautiful” match with temozolomide, Avant CEO tells “The Pink Sheet” DAILY.

You may also be interested in...



Pfizer Axes Deal For Brain Cancer Vaccine, Leaves Partner Celldex In the Lurch

A brave face: Celldex execs say they are ready and able to take brain cancer vaccine CDX-110 into Phase III without a Big Pharma partner.

Pfizer Axes Deal For Brain Cancer Vaccine, Leaves Partner Celldex In the Lurch

A brave face: Celldex execs say they are ready and able to take brain cancer vaccine CDX-110 into Phase III without a Big Pharma partner.

Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO

Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in

Related Content

Topics

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel